Phase 1 ALS Trial is First to Test Antisense Treatment of Neurodegenerative Disease

News   Apr 09, 2013

 
Phase 1 ALS Trial is First to Test Antisense Treatment of Neurodegenerative Disease
 
 
 
FURTHER INFORMATION
 

This content appears on:

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks, Log In or Join Today

Login Join
 
 

Comments | 0 ADD COMMENT